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OBJECTIVES The purpose of this study was to elucidate whether cardiac beta-adrenergic effects may be
blunted in patients on maintenance hemodialysis (HD) and may help to explain autonomic
dysfunction.
BACKGROUND Patients on HD often suffer from autonomic dysfunction.
METHODS We investigated the cardiovascular response of five HD patients (age: 46.1 6 7.9 years) and
six healthy volunteers (age: 48.2 6 7.5 years) to isoprenaline, pirenzepine and phenylephrine.
For analysis of underlying mechanisms of beta-adrenoceptor hyporesponsiveness, six-week-
old male Wistar rats were rendered uremic by 5/6-nephrectomy (n 5 9; SNX) and were killed
for removal of the heart after six to seven weeks. Sham-operated rats (n 5 15) served as
controls.
RESULTS In the patient study, isoprenaline (3.5, 7, 17, 35 ng/kg/min, i.v.) led to an increase in heart
rate, and shortening of the heart rate corrected duration of the electromechanical systole
(QS2c), both of which were significantly reduced in HD patients. Baroreflex sensitivity was
significantly reduced in HD patients. The response to low parasympathomimetic doses of
pirenzepine was unchanged. In the rat study, left ventricular strips were placed in an organ
bath, electrically driven and exposed to isoprenaline (10211 to 1026 mol/liter). While pD2
values were unchanged, maximum effect at the highest concentration was significantly
reduced in SNX rats. The response to carbachol was not altered, nor was the M2-
cholinoceptor density. There was no difference in beta-adrenoceptor density, or in immuno-
detectable amount of Gs and Gi protein. Activation of adenylyl cyclase evoked by isoprenaline was
significantly reduced in left ventricular membranes of SNX rats, whereas effects of 10 mmol/liter
GTP, 10 mmol/liter NaF, 10 mmol/liter forskolin and 10 mmol/liter Mn21 were not altered.
CONCLUSIONS Cardiac beta-adrenergic responses are blunted in chronic uremia due to reduced isoprenaline-
dependent activation of adenylyl cyclase. This might be caused by an “uncoupling” of the
receptor or by an inhibition of the receptor by uremic toxins. (J Am Coll Cardiol 2000;36:
608–17) © 2000 by the American College of Cardiology
A common problem in patients on maintenance hemodial-
ysis (HD) is the development of an autonomic dysfunction
(1–3) with impaired baroreflex control (4,5). Thus, acute
hypotension occurs in up to 30% of the patients (6–8).
Hyporesponsiveness to adrenergic stimuli, characterized by
reduced increase in heart rate after isoprenaline administra-
tion, has been shown in uremic, predialysis patients (9) and
in patients on HD (10,11), as well as diminished barore-
ceptor sensitivity (4,10). Moreover, Campese and colleagues
(9) could demonstrate attenuated cardiovascular responses
to norepinephrine in patients with chronic renal failure
(predialysis state) and with elevated plasma norepinephrine
levels (12,13). While previous investigations were focused
on the role of alpha-adrenoceptors (10,14), only little is
known on the role of beta-adrenoceptors and beta-
adrenoceptor signaling in HD patients.
Regarding end-organ responsiveness to catecholamines, a
reduced response in heart rate to isoproterenol in HD
patients was found (15,16). In addition, reduced (-)[125I]-
iodocyanopindolol [(-)[125I]ICYP] binding to rat lung beta-
adrenoceptors if incubated with uremic plasma has been
reported (17) due to interference of endogenous uremic
substances on the beta-adrenergic receptors (18). In a 48-h
rat model of acute uremia, the effect of isoprenaline on heart
rate and adenylyl cyclase activity was reduced (19). How-
ever, it remains unclear whether this may also play a role in
chronic uremia. In addition, the role of beta-adrenoceptor
density and subtype distribution is unclear, because Mann
and coworkers (19) found no change in beta-adrenoceptor
density but reduced beta-adrenoceptor responsiveness,
while others found enhanced beta2-adrenoceptor densities
on mononuclear cells in patients (20). Furthermore, Gs and
Gi proteins, as the link between beta-adrenoceptor and adeny-
lyl cyclase, have not been investigated in chronic uremia.
Thus, the purpose of the present study was to find out
whether cardiac beta-adrenoceptor responses were altered in
patients on HD. We found a reduced heart rate and reduced
positive inotropic response to isoprenaline and studied the
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possible underlying mechanism in a rat model assessing
cardiac beta-adrenoceptor density, beta1/beta2-adrenoceptor-
ratio, Gs and Gi proteins and adenylyl cyclase activity.
METHODS
Human study. Six healthy volunteers (three men, three
women, age: 48.2 6 7.5 [22–67.5] years; at least six weeks
drug-free) and five patients (two men, three women, age:
46.1 6 7.9 [24–65] years; medication: see Appendix) with
chronic renal failure on HD (dialysis frequency: 3–4 h/week
over a period of at least 2 years, mean: 4.4 6 1.4 years;
uremia was caused by glomerulonephritis [two], pyelone-
phritis [one] polycystic kidney disease [one] and sclerotic
kidney [one]) were studied. The study protocol was ap-
proved by the Ethical Committee of the University of
Halle-Wittenberg, and written informed consent was ob-
tained from all participants. Only patients that did not
exhibit signs of acute infection, asthma, chronic pulmonary
disease or clinical signs of acute decompensation were
included in the study. The patients on HD had an ejection
fraction of 62.2 6 4.1%, a left ventricular end-diastolic
diameter of 49.4 6 5.5 mm and left ventricular end-systolic
diameter of 35 6 5.5 mm; plasma norepinephrine was
447 6 176 pg/ml and epinephrine was 30 6 4.3 pg/ml
(“normal” values for this test [18]: norepinephrine: 150–
275, epinephrine: 25–35 pg/ml).
After 30 min of rest in supine position in an air-
conditioned (21°C), quiet room, baseline hemodynamic
parameters were assessed. Thereafter, either isoprenaline
(3.5, 7, 17, 35 ng/kg/min) (n 5 4 patients, n 5 6
volunteers) or (on another examination day) phenylephrine
(0.1, 0.2, 0.5, 1.0 mg/kg/min) (n 5 5 patients, n 5 6
volunteers) was infused intravenously for 10 (isoprenaline)
or 15 (phenylephrine) min per dose. In another protocol,
the patients and volunteers received pirenzepine in low
doses, which are known to exert parasympathomimetic
effects (21–23). After 30 min of rest in supine position,
pirenzepine (sequential doses of 0.16, 0.32, 0.64, 1.25 mg)
was injected intravenously over 5 min, each dose step
requiring 20 min. The interval between each experimental
protocol was at least one week. Experiments were always
carried out at the end of the long dialysis-free interval.
Cardiovascular effects of drug infusion were analyzed by
assessing systolic and diastolic blood pressure, heart rate and
systolic time intervals. During the study, an electrocardio-
gram was continuously monitored, from which heart rate
was determined over 20 cardiac actions (20 RR intervals).
Blood pressure was measured five times in the last 5 min of
each dose step using a common sphygmomanometer (Dip-
lomat Presameter). If the increase in systolic blood pressure
exceeded 50 mm Hg or the decrease in diastolic blood
pressure was more than 30 mm Hg, the infusion of the drug
was terminated for safety reasons. Systolic time intervals
were measured in the last minute of each dose step by
simultaneous recording of a electrocardiogram, a phonocar-
diogram and the carotid pulse tracing (Bioset 8000 mul-
tichannel recorder; Ho¨rmann Medizintechnik, Zwo¨nitz,
Germany) at high paper speed (100 mm/s). Heart rate
corrected duration of the electromechanical systole (QS2c)
was defined as the time interval between Q-spike of the
peripheral electrocardiogram and the first high-frequency
component of the phonocardiogram and was corrected for
heart rate revealing QS2c as previously described (24).
Baroreceptor sensitivity was assessed according to the
method first described by Smyth et al. (25) by infusion of
cumulative doses of phenylephrine and monitoring heart
rate and blood pressure. Calculating the linear regression for
the changes in heart rate over the changes in systolic blood
pressure reveals a linear function of Y 5 A 1 B 3 X, the
slope of which is an indicator of the baroreceptor-reflex
sensitivity (26,27). This phenylephrine method has been
recently confirmed to be appropriate in clinical tests (28).
Animal study. All animal experiments were performed
according to the German laws for animal welfare and were
approved by the local committee for animal studies. Male
Wistar rats (six weeks old) were submitted to 5/6 nephrec-
tomy (SNX) that is, subtotal, as described by Amann et al.
(29). Briefly, the right kidney was removed under light
anesthesia (ketamine), and one week later, the left kidney
was resected (resection of the lower and upper kidney pole,
leaving an intact kidney segment in between) (SNX, n 5
40). Concomitantly, a group of rats was sham operated
(SOP, n 5 42). After the first operation, the SOP rats
received the same amount of food as the operated SNX rats
had consumed the previous day (diet consisting of 22.5%
protein, 0.2% Na1 and 1% K1; Altromin, Lage, Germany).
The experiment was terminated six to seven weeks after the
second operation by sacrificing the rats by cervical disloca-
tion.
Contractile responses. After sacrificing the rats, the rats’
hearts were removed, placed into oxygenated Krebs-
Henseleit solution and trabecular strips of 1 mm to 2 mm
width, 1 mm to 1.5 mm thickness and 6 mm to 8 mm
length were prepared from the left ventricle. These strips
were placed in 10-ml organ baths containing Tyrode solu-
tion of the following composition (NaCl 136.9, KCl 5.4,
Abbreviations and Acronyms
DBP 5 diastolic blood pressure
HD 5 maintenance hemodialysis
HR 5 heart rate
MAP 5 mean arterial pressure
QS2c 5 heart rate corrected duration of the
electromechanical systole
PSL 5 photostimulated luminescence
SBP 5 systolic blood pressure
SNX 5 5/6-nephrectomized rat
SOP 5 sham-operated rat
(-)[125I]ICYP 5 (-)[125I]-iodocyanopindolol
[3H]NMS 5 [3H]N-methyl-scopolamine
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CaCl2 2.5, MgCl2 1.05, NaH2PO4 0.42, NaHCO3 25.0,
glucose 9.7 mmol/liter, equilibrated with 95% O2 and 5%
CO2, 37°C) and electrically driven (1 Hz) with rectangular
pulses (5 ms) 50% above threshold (1–4 V, mean: 2.5 V)
(Stimulator II; Hugo Sachs Elektronik, Hugstetten, Ger-
many). After prestretching the preparation (10 mN), the
developed force was recorded via a strain gauge on a Hellige
recorder (Hellige, Freiburg, Germany). After 60 min of
equilibration, cumulative concentration response curves for
isoprenaline (10210 to 1026 mol/liter) and calcium (2.5 to
13 mmol/liter) were carried out as detailed elsewhere (30).
To evaluate a possible functional role for beta2-
adrenoceptors in these preparations, we assessed the effects
of isoprenaline (10210 to 1023 mol/liter) in the absence or
presence of either 3 3 1027 mol/CGP 20712A or 3 3 1027
mol/CGP 20712A plus 5 3 1028 mol/liter ICI 118.551 in
additional experiments (n 5 5–7).
In additional experiments (n 5 3 for each group), the
reactivity to a parasympathomimetic stimulus was tested by
application of cumulative concentrations of carbachol (1029
to 1025 mol/liter) after prestimulation of the strips with 3
mmol/liter forskolin.
Radioligand binding study. Beta-adrenoceptors were as-
sessed by (-)[125I]-ICYP-binding assay detailed elsewhere
(23). Briefly, tissues were homogenized in 10 volumes
ice-cold 1 mmol/liter KHCO3 with an Ultra Turrax (Janke
and Kunkel, Staufen, Germany), diluted to 20 ml with 1
mmol/liter KHCO3, centrifuged at 700 g for 15 min, passed
through four layers of cheesecloth and centrifuged again at
50,000 g for 20 min. Pellets were washed once by resuspen-
sion and recentrifugation and finally resuspended in incu-
bation buffer (Tris-HCl 10, NaCl 154, ascorbic acid 0.55
mmol/liter, pH 7.4, 25°C) at a protein concentration of
0.1–0.2 mg/ml. Protein content was determined by the
method of Bradford (31) using bovine immunoglobulin G
as a standard.
The density of beta-adrenoceptors in cardiac membranes
was determined by (-)[125I]ICYP binding at six concentra-
tions ranging from 5 to 200 pmol/liter. Nonspecific binding
of ICYP was defined as binding to membranes that could
not be displaced by a high concentration of the nonselective
beta-adrenoceptor antagonist (6) CGP 12177 (1 mmol/
liter). Specific binding was defined as total binding minus
nonspecific binding and normally was about 70 % to 80% at
50 pmol/liter ICYP.
To determine the relative amounts of beta1- and beta2-
adrenoceptors, membranes were incubated with ICYP (100
pmol/liter) in the absence or presence of six concentrations
(from 1029 to 1024 mol/liter) of the selective beta1-
adrenoceptor antagonist CGP 20712A, and the specific
binding assessed as described above. CGP 20712A compe-
tition curves were analyzed using the iterative curve fitting
program InPlot (GraphPad Software, San Diego, CA).
Statistical analysis was performed by using the F-ratio test
to measure the goodness-of-fit of the competition curves for
either one or two binding sites.
M2 muscarinic receptors were determined by [
3H]N-
methyl-scopolamine ([3H]NMS) binding as recently de-
scribed (32). Briefly, tissue was homogenized as described
above. After filtering the supernatant of the first centrifu-
gation step through cheesecloth, it was centrifuged at
21,000 g for 45 min; the pellets were resuspended in the
incubation buffer (Na2HPO4 10, NaH2PO4 10, pH 7.4) to
yield a protein concentration of 0.6 mg/ml to 0.7 mg/ml.
The M2 muscarinic receptor density was assessed at six
different concentrations of [3H]NMS ranging from 0.1 to
10 nmol/liter as detailed elsewhere (32). Nonspecific bind-
ing of [3H]NMS was determined as radioactivity bound to
membranes that was not displaced by atropine (1 mmol/
liter). Specific binding was defined as total minus nonspe-
cific binding. Statistical analysis was performed as described
above.
G-protein assay. Immunodetectable Gs and Gi subunits
were measured by quantitative immunoblotting as described
previously (23). Briefly, aliquots of the membrane prepara-
tions (approximately 100 mg protein/sample) were separated
on sodium dodecyl sulphate polyacrylamide gels (10% acryl-
amide in the running gel) and thereafter blotted overnight
to nitrocellulose membranes (Hybond, ECL; Amersham) at
a constant voltage of 55 V. The blots were washed and
incubated overnight at 4°C with a 1:500 dilution of the
indicated antisera. The blots were washed again twice and
then incubated for 1 h at room temperature with [125I]pro-
tein A solutions (8.5 mCi/mg, 129 mCi/ml). After another
four washes, the blots were exposed on imaging plates (Fuji
Photo Film Co. Ltd, Japan) for 2 h to 24 h depending on
the actual radioactivity. Detection and quantification of the
G-proteins were carried out by using the Bio-Imaging Ana-
lyzer BAS 2000 (Fuji Photo Film Co. Ltd.) equipped with
the data analyzing program Tina 2.10 fram raytest (Iso-
topenmessgera¨te, Straubenhardt, Germany). Photostimu-
lated luminescence (PSL) was determined, background
luminescence was subtracted and the results expressed as
densitometric units (d.u.). Using the autoradiograms, the
molecular weights of the specific bands were identified.
Protein dependency was established for each antibody. To
allow the detection of possible increases or decreases,
protein amounts corresponding to the middle of the
linear part of the protein dependency curves were used.
Adenylyl cyclase activity. The procedure for determina-
tion of adenylyl cyclase activity has been previously de-
scribed in detail (23). In brief, membranes (30 mg to 40 mg
protein) were incubated for 10 min at 30°C in a final volume
of 100 ml containing 40 mmol/liter Hepes buffer (pH 7.4),
5 mmol/liter MgCl2, 1 mmol/liter EDTA, 10 mmol/l GTP,
500 mmol/liter ATP, about 100,000 cpm [a-32P]ATP, 100
mmol/liter cAMP and an ATP regenerating system (5
mmol/liter phosphocreatine and 50 U/ml creatine phos-
phokinase) in the presence or absence of isoprenaline (1028
to 1025 mol/liter). In additional experiments, the effect of
10 mmol/liter forskolin, 10 mmol/liter NaF, 10 mmol/liter
GTP or 10 mmol/liter Mn21 was assessed. For GTP, NaF
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and forskolin activation membranes were incubated in the
buffer as described above but without GTP; for Mn21
activation, membranes were incubated in this buffer without
GTP and Mg21. In all experiments, the reaction was
stopped by the addition of 100 ml buffer containing 50
mmol/liter Tris, 40 mmol/liter ATP, 1.4 mmol/liter cAMP,
2% SDS and [3H]cAMP (about 10,000 cpm) at pH 7.5;
800 ml H2O was then added. The mixture was poured into
a Dowex AG 50W-X4 anion-exchange column (mesh size:
200–400; hydrogen form) and ATP was eluted twice with
1 ml water. The columns were then placed over neutral
alumina columns, and cAMP was eluted from the Dowex
columns with 4 ml water. The alumina columns were placed
over scintillation vials, and the cAMP was eluted from the
alumina columns with 5 ml 0.1 mol/liter imidazole (pH
7.3). Fifteen milliliters Lumasafe plus scintillator was added
to the eluate and counted at 42% efficiency. The determined
amount of [3H]cAMP in each vial was used to calculate the
recovery of cAMP for each column, and the amount of
[32P]cAMP collected from each column was corrected for
the recovery rate, which usually was in the range of 70% to
80%.
Statistics. All values are presented as means 6 SEM of n
experiments. Experimental data (rats) were fitted and ana-
lyzed by computer-supported iterative nonlinear regression
analysis using the InPlot program (GraphPAD Software).
Statistical significance of differences was analyzed by un-
paired two-tailed Student’s t test or, if appropriate, by
repeated measures analysis of variance followed by t test
using Bonferroni corrections for multiple comparisons. A
p , 0.05 was considered to indicate a significant difference.
The statistical evaluation was performed using the InStat
program (GraphPAD Software).
Chemicals. Chemicals were obtained from the following
sources: isoprenaline (patients) (Aleudrina; Boehringer In-
gelheim, Ingelheim, Germany), (-)isoprenaline bitartrate,
atropine sulfate for the animal experiments and carbachol
(Sigma, Deisenhofen, Germany), phenylephrine (Neo-
Synephrine; Sanofi-Winthrop, New York, New York),
pirenzepine (Gastrozepine; Thomae, Biberach, Germany),
CGP 20712A (kindly donated by Ciba Geigy, Basel,
Switzerland), ICI 118.551 (kindly donated by ICI Pharma,
Planckstadt, Germany); [3H]-N-methylscopolamine (spe-
cific activity 85 Ci/mmol), (-)[125I]ICYP (specific activity:
2,200 Ci/mmol), [125I]-protein A (8.5 mCi/mg),
[a-32P]ATP (specific activity 30 Ci/mmol) and [3H]cAMP
(specific activity 44.5 Ci/mmol) (New England Nuclear,
Dreieich, Germany). All other chemicals were of the purest
commercially available grade. The antibodies AS/7 and
RM/1, which specifically recognize GIa1/2 and Gsa, respec-
tively (33), were obtained from New England Nuclear.
RESULTS
Human study. Systolic, mean and diastolic blood pressure,
as well as QS2c at baseline, that is, assessed after 30 min of
rest in supine position, were not significantly different
between both groups, as can be seen in Table 1. Only the
heart rate was elevated in patients on HD. Isoprenaline
infusion caused a dose-dependent increase in heart rate (Fig.
1) and shortening QS2c (Fig. 2). Both responses were
significantly attenuated in patients on HD (maximum
change at the highest dose used: heart rate, 43.8 6 3.4 vs.
33.8 6 4.3 beats/min, p , 0.05; QS2c, 299.7 6 7.6 vs.
273.1 6 8.4 ms, p , 0.05).
Baroreflex sensitivity was assessed by monitoring changes
in heart rate and in systolic blood pressure while infusing
cumulative doses of phenylephrine, which resulted in a
dose-dependent increase in systolic blood pressure and
decrease in heart rate in both groups (Table 2).
Thereafter, changes in heart rate were plotted against
changes in systolic blood pressure, and a linear regression of
the form Y 5 A 1 B 3 X was fitted. We found no change
of the Y-axis intercept A (healthy, 22.5 6 0.14; patients on
HD, 22.1 6 0.58), while the slope B of the function was
Figure 1. The effect of intravenous isoprenaline on changes in heart rate
(beat/min) in HD patients and healthy volunteers. Values are given as
means 6 SEM. Significant differences between both groups are indicated
by an asterisk (p , 0.05). Basal values: HD patients, 66 6 4 (n 5 4);
healthy, 55 6 3 beats/min (n 5 6).
Table 1. Baseline Parameters (Human Study)
Group
Age
(years)
Body Weight
(kg)
SBP
(mm Hg)
DBP
(mm Hg)
MAP
(mm Hg)
HR
(bpm)
QS2c
(ms)
HD patient 46 6 8 62 6 5 120 6 7 72 6 6 92 6 5 73 6 6* 503 6 11
Healthy 48 6 8 66 6 4 118 6 5 79 6 2 96 6 3 55 6 3 511 6 10
Baseline values of all HD patients (n 5 5) and healthy volunteers (n 5 6) after 30 min of rest in supine position. Values are given
as means 6 SEM. There were no significant differences between both groups except a higher heart rate in HD patients (p ,
0.05). SBP 5 systolic blood pressure; DBP 5 diastolic blood pressure; MAP 5 mean arterial pressure; HR 5 heart rate; QS2c
5 heart rate corrected duration of the electromechanical systole.
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significantly lower in patients on HD (healthy, 20.41 6
0.01; patients on HD, 20.32 6 0.04 beats/min/mm Hg,
p , 0.05; R was .0.9 for both fits), indicating a reduced
baroreflex sensitivity in these patients (Fig. 3).
Injection of low doses of pirenzepine (0.16 mg to
1.25 mg) resulted in a significant (p , 0.05) decrease in
heart rate but without any difference between both groups,
as shown in Figure 4. Pirenzepine led to slight but not
significant prolongation of QS2c from 514.3 6 6.22 ms
(healthy) to 522.2 6 6.17 ms (healthy) and from 509.9 6
8.73 ms to 511.9 6 10.6 ms (patients on HD).
Rat study. First, the rat model of chronic uremia was
characterized. In rats rendered uremic by 5/6 nephrectomy,
we found elevated plasma creatine (SOP, 50.2 6 1.4, n 5
34; SNX, 77.9 6 1.6 mmol/liter, n 5 42, p , 0.05) and urea
values (SOP, 7.2 6 0.3, n 5 34; SNX, 11.5 6 0.5
mmol/liter, n 5 42, p , 0.05) six to seven weeks after
operation. Both groups did not differ with regard to their
body weight (SOP, 314 6 6, n 5 42; SNX, 309 6 4, n 5
40; NS). In contrast, in uremic rats, cardiac hypertrophy
became obvious (cardiac index: SOP, 3.24 6 0.05, n 5 42;
SNX, 3.78 6 0.06 mg/g, n 5 40, p , 0.05), which was due
to hypertrophy of the left ventricle. Thus, left ventricular
cardiac index was significantly enhanced (SOP, 1.89 6
0.07, n 5 15; SNX, 2.6 6 0.13 mg/g, n 5 23, p , 0.05),
while right ventricular cardiac index remained unchanged
(SOP, 0.52 6 0.03, n 5 15; SNX, 0.57 6 0.02 mg/g, n 5
23, NS). Systolic blood pressure, measured at the tail vein,
was slightly elevated in uremic rats (SOP, 122.2 6 1.6, n 5
20; SNX, 130.8 6 4.4 mm Hg, n 5 28, NS, p 5 0.12).
Plasma epinephrine levels did not differ between both
groups (SOP, 20 6 18, n 5 11; SNX, 36 6 16 pg/ml, n 5
11, NS), whereas plasma norepinephrine was significantly
increased in uremic rats (SOP, 285 6 28, n 5 11; SNX,
400 6 68 pg/ml, n 5 11, p , 0.05).
Exposure of the left ventricular strips to cumulative
concentrations of isoprenaline (10211 to 1026 mol/liter) led
to a concentration-dependent increase in contractile force in
both groups. However, while pD2 values were not altered
(SOP, 7.9 6 0.02, n 5 11; SNX, 8.1 6 0.02, n 5 11), the
maximum effect at the highest concentration was signifi-
cantly reduced in uremic rats (SOP, 5.16 6 0.11, n 5 11;
SNX, 3.22 6 0.07 mN, n 5 11, p , 0.05) (Fig. 5A). For
control, the inotropic response to external CaCl2 was
investigated. It became obvious that the calcium-induced
increase in force was not significantly different between both
groups: maximum increase was observed after application of
8 mmol/liter CaCl2, as can be seen in Figure 5B.
In additional experiments, we investigated the functional
role of cardiac beta1- and beta2-adrenoceptors in SOP (n 5
5) and SNX (n 5 7) rats. The addition of 3 3 1027
mol/liter CGP20712A led to a similar rightward shift of the
isoprenaline concentration response curve in both groups.
The addition of 5 3 1028 ml/liter ICI 118.551 had no effect
on this rightward shift in both groups (pD2 values: SNX:
isoprenaline, 8.05 6 0.05; CGP, 4.84 6 0.06; CGP
20712A 1 ICI 118.551: 4.85 6 0.05, n 5 7; SOP:
isoprenaline, 7.84 6 0.05, CGP, 5.30 6 0.11; CGP
Figure 2. The effect of intravenous isoprenaline on changes in the duration
of the heart rate corrected electromechanical systole (QS2c) (ms) in HD
patients and healthy volunteers. Values are given as means 6 SEM.
Significant differences between both groups are indicated by an asterisk
(p , 0.05). Basal values: HD patients, 505 6 16 (n 5 4); healthy, 511
610 ms (n 5 6).
Figure 3. Changes in systolic blood pressure induced by phenylephrine
infusion versus changes in heart rate in HD patients (n 5 5) and healthy
volunteers (n 5 6) indicating baroreflex sensitivity. Result of the linear
regression is indicated by a solid line for healthy volunteers and by a
dashed line for HD patients. Data of linear regression are given in the text.
Table 2. Effect of Phenylephrine Infusion in HD Patients and Volunteers
Group Parameter Baseline 0.1 mg/kg/min 0.2 mg/kg/min 0.5 mg/kg/min 1.0 mg/kg/min
Healthy SBP 118 6 5 117 6 5 121 6 6 128 6 7 139 6 8
HR 58 6 2 56 6 3 55 6 2 52 6 2 47 6 3
HD patient SBP 120 6 7 123 6 8 123 6 7 131 6 12 149 6 16
HR 73 6 6 71 6 6 64 6 3 60 6 3 57 6 3
Effect of intravenous phenylephrine infusion on SBP (mm Hg) and HR (bpm) in healthy volunteers (n 5 6) and HD patients
(n 5 5). Values are given as means 6 SEM. HD 5 hemodialysis; HR 5 heart rate; SBP 5 systolic blood pressure.
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20712A 1 ICI 118.551, 4.92 6 0.1, n 5 5). The KB for
CGP 20712A was 0.8 6 0.3 or 0.2 6 0.1 nmol/liter in SOP
and SNX rats, respectively (not significantly different).
To investigate the cardiac M2-receptor function, we
applied carbachol (1029 to 1025 mol/liter) after stimulation
with 3 mmol/liter forskolin in three additional experiments.
Carbachol led to the expected decrease in contractile force
without differences between both groups (pD2 values: SOP:
6.48 6 0.28, n 5 9; SNX, 6.16 6 0.16, n 5 9) (Fig. 5C).
Regarding the density of M2 cholinoceptors (assessed by
[3H]NMS binding), we found no significant difference
between SNX and SOP rats (SNX: 65.9 6 7 fmol/mg
protein, n 5 11, vs. SOP: 62.6 6 8.9 fmol/mg protein, n 5
12, NS). The KD values for [
3H]NMS were not different
between both groups (SNX: 0.7 6 0.15 nmol/liter, n 5 11,
vs. SOP: 0.64 6 0.1 nmol/liter, n 5 12, NS).
To investigate the mechanism underlying the reduced
contractile response to isoprenaline (mentioned above) but
not to calcium, we assessed the components of the beta-
adrenoceptor-G-proteins-adenylyl cyclase system in left
ventricular tissue.
Left ventricular beta-adrenoceptor density as assessed by
(-)[125I]ICYP binding was not different between both
groups (SOP: 21 6 2.9, n 5 11; SNX: 23.1 6 3.9 fmol/mg,
n 5 11). In addition, beta1:beta2-adrenoceptor ratio, as
determined from competition curves of the highly selective
beta1-adrenoceptor antagonist CGP 20712A (10
210 to
1021 mol/liter) with the ICYP binding (100 pmol/liter),
was not significantly altered in uremic rats (beta1-
adrenoceptors: SOP, 65.7 6 1.7%, n 5 11; SNX: 68.6 6
1.4%, n 5 10, NS).
Next, we investigated the immunodetectable amount of
the G proteins Gs and Gi in the left ventricles. The
Gs-specific antiserum RM/1 detected two bands with mo-
lecular weights of 45 and 53 kDa corresponding to Gsa-short
and Gsa-long. No significant differences could be detected
between SOP and SNX rats (53 kDa Gs: SOP, 1,093 6
102, n 5 6; SNX, 855 6 107, n 5 6, NS; 45 kDa Gs: SOP,
1,517 6 135, n 5 6; SNX, 1,279 6 131 densitometric units,
n 5 6, NS).
The antiserum AS/7, which recognizes the alpha subunits
of Gi1, Gi2 and transducin, detected one band with an
apparent molecular mass of 43 kDa; no significant difference
in this band between SOP and SNX rats could be detected
(Gi: SOP, 206 6 28, n 5 7; SNX, 181 6 24 densitometric
units, n 5 5, NS).
Finally, we assessed adenylyl cyclase activity in left ven-
tricular membranes from SNX and SOP rats. Basal activi-
ties did not differ between both groups (Table 3). However,
the isoprenaline-induced activation of adenylyl cyclase was
at each concentration significantly larger in SOP than it was
in SNX rats (Fig. 6). Thus, at maximum stimulation (with
1025 mol/liter isoprenaline), cAMP formation was signifi-
cantly diminished in uremic rats (SOP: 42.9 6 5, n 5 9;
SNX: 27.5 6 4.7, n 5 7, p , 0.05). pEC50 values of
isoprenaline, however, were not different between SOP
(8.18 6 0.25, n 5 9) and SNX (7.95 6 0.24, n 5 7) rats.
On the other hand, activation of adenylyl cyclase by 10
mmol/liter NaF, 10 mM forskolin, 10 mmol/liter GTP or 10
mmol/liter Mn21 did not differ between SNX and SOP rats
(Table 3).
DISCUSSION
Human study: Cardiac beta-adrenoceptor responses and
baroreflex sensitivity are reduced in chronic HD patients.
A common problem in patients on chronic hemodialysis is
the development of an autonomic dysfunction (1), including
decreased responsiveness of vascular a-adrenoceptors (34),
increased plasma norepinephrine levels and a reduced
baroreceptor sensitivity (4,5,10,11), as was also seen in our
study. Increased plasma norepinephrine levels and decreased
baroreflex sensitivity (35–38) are also found in patients with
chronic heart failure, and it is well known that in these
patients, cardiac beta-adrenoceptor function is decreased
(for review see reference 39). However, relatively little was
known on cardiac beta-adrenoceptors in patients on HD.
Thus, we first investigated the effects of isoprenaline on
heart rate and QS2c (as a measure of inotropism [40]) in
patients on HD and controls. The results clearly demon-
strate that both the increase in heart rate and the shortening
of QS2c were blunted in patients on HD, which cannot be
due to age-dependent changes, because both groups were
age matched. Thus, beta-adrenoceptor responsiveness ap-
pears to be decreased.
While isoprenaline effects on heart rate are mediated
through beta1- and beta2-adrenoceptors (for review see
references 39,41), its effects on contractility appear to be
predominantly mediated via beta1-adrenoceptor stimulation
(24). Thus, it can be concluded that in these patients
beta1-adrenoceptors in the heart are desensitized. Unfortu-
nately, we could not test whether beta2-adrenoceptor re-
sponses are also changed in these patients.
Figure 4. The effect of intravenous injection of pirenzepine (0.16, 0.32,
0.64 and 1.25 mg, 20 min per dose step) on heart rate in healthy volunteers
(n 5 6) and HD patients (n 5 5). Values are given as means 6 SEM..
There were no significant differences between both groups. Baseline heart
rate: healthy, 57 6 2; HD patients, 70 6 3 beats/min; p , 0.05).
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Because both the sympathetic and parasympathetic path-
ways control heart rate, it was also necessary to investigate
the responsiveness to parasympathomimetic stimuli. Re-
cently, we demonstrated that low doses of the M1-receptor
antagonist pirenzepine decreased heart rate in humans
possibly via inhibition of presynaptic muscarinic autorecep-
tors, thus enhancing release of endogenous acetylcholine
(32). Because we did not observe a difference in the
pirenzepine-induced decrease in heart rate between patients
on HD and normal subjects, it can be concluded that
muscarinic receptor function is probably not altered, a
conclusion shared with other investigators (10), although
Zoccali and coworkers (42) did find reduced parasympa-
thetic activity (however, unrelated to duration of hemodi-
alysis).
Regarding the underlying mechanisms, only a few studies
on beta-adrenoreceptors, mainly on blood cells such as
lymphocytes, have been performed in chronic HD patients.
Thus, reduced beta2-adrenoceptor responsiveness (in lym-
phocytes) was observed (43,44) with unchanged beta2-
Figure 5. (A) Changes in the contractile responses of isolated left ventricular strips of uremic (SNX) and sham-operated (SOP) rats to cumulative
concentrations of isoprenaline. Control values: SNX, 4.5 6 0.27 (n 5 15); SOP, 3.5 6 0.24 mN (n 5 9). (B) Changes in the calcium-induced positive
inotropic response in SOP and SNX rats. Control values: SNX, 2.3 6 0.3 mN (n 5 15); SOP, 1.67 6 0.2 mN (n 5 9). (C) Decrease in contractile force
in ventricular strips prestimulated with 3 mmol/liter forskolin by cumulative concentrations of carbachol in SOP (n 5 3) and SNX (n 5 3) rats. Control
values after preconstriction with 3 mmol/liter forskolin: SNX, 5.7 6 0.4 mN (n 5 3); SOP, 6.5 6 0.7 mN (n 5 3). All values are given as means 6 SEM.
Significant differences between both groups are indicated by an asterisk (* 5 p , 0.05; ** 5 p , 0.01; *** 5 p , 0.001).
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adrenoceptor number (43), while increased beta2-
adrenoceptor density and increased epinephrine levels were
found by others (17), which was interpreted as an indication
for endogenous uremic substances blocking the beta-
adrenoceptors. Many substances, including polyols, sugars,
3-D-hydroxybuyrate, dimethylglycine, sulfoconjugated cat-
echolamines and others (45,46), have been found to be
increased in uremic plasma. Ferchland and coworkers (18)
showed that such endogenous uremic substances can inhibit
beta-adrenoceptor binding, which may contribute to the
reduced responsiveness to isoprenaline in vivo.
Regarding the impaired baroreflex, it should be noted
that the patients included in our study were normotensive
and on hemodialysis for 4.4 years. The differentiation seems
to be necessary because Armengol et al. (11) showed that
normotensive HD patients (mean duration of hemodialysis,
3.2 years) exhibited less pronounced disturbance of auto-
nomic tests, while in hypotensive subjects (mean duration of
hemodialysis, 10.8 years), the impairment of the autonomic
function was more distinct. However, the overall integrity of
the baroreflex was impaired in both normotensive and
hypotensive hemodialysis patients (10,11). The reduced
responsiveness to isoprenaline observed in our study indi-
cates a possible impairment of the efferent sympathetic
branch.
Rat study: Cardiac beta-adrenoceptor responses are re-
duced in chronic uremic rats. In order to study the
mechanisms underlying the beta-adrenoceptor hyporespon-
siveness, we decided to investigate the components of the
beta-adrenoceptor system, i.e., beta-adrenoceptor,
G-proteins and adenylyl cyclase in cardiac tissue in a rat
model of chronic uremia, the subtotally nephrectomized rat.
This rat model exhibited a similar decrease in isoprenaline
response as observed in humans (Fig. 5A) and elevated
plasma norepinephrine levels but unaltered plasma epineph-
rine levels as seen in HD patients and as described in the
literature (19). Furthermore, similar to HD patients, an
unchanged cardiac M2-receptor function was found in these
uremic rats. Thus, this rat model seems to be suitable to
serve as a model, at least partly, of chronic hemodialysis
patients as investigated in this study.
The beta-adrenergic hyporesponsiveness seen in our
study may be caused by either reduced beta-adrenoceptor
density (as common in heart failure [39]), by blockade of the
receptors by endogenous substances or by a defect in the
signaling cascade. In our study, beta-adrenoceptor density
was found to be unchanged, indicating the absence of
beta-adrenoceptor downregulation, which is in accordance
with the other findings (19). In addition, the cardiac
beta1/beta2 distribution was not altered. Accordingly, the
rightward shift of the isoprenaline concentration response
curve by CGP 20712A was not altered in uremic rats, and
in both groups, additional ICI 118.551 had no effect on the
curve. In sum, this means that the positive inotropic effect of
isoprenaline is mediated via beta1-adrenoceptors in rats,
which agrees with the literature (30,39), and that in uremic
rats the beta1-adrenoceptor responsiveness is reduced.
Furthermore, the immunodetectable amount of Gsa and
GIa was not different between SNX and SOP rats, although
Gsa (both the short and the long form) showed a tendency
to decrease. Moreover, activation of adenylyl cyclase by
GTP (acting at Gs and Gi [23,47]) and NaF (acting under
these experimental conditions at Gs [48]) did not differ
between both groups of rats, indicating unchanged func-
tional activities of Gs and Gi.
Activation of adenylyl cyclase by forskolin (acting pre-
dominantly at the catalytic unit of the enzyme, but involving
partly Gs [23,47,49]) and Mn
21 (acting at the catalytic unit
[50]) was not different between SNX and SOP rats; this is
in agreement with the idea of an unchanged adenylyl cyclase
activity in chronic uremia. On the other hand, isoprenaline-
induced activation of adenylyl cylase was at each concentra-
tion higher in SOP rats than in SNX rats. Thus, in chronic
uremic rat hearts, beta-adrenoceptor number, amount and
activity of G proteins and activity of adenylyl cyclase are not
changed, while beta-adrenoceptor responsiveness (activa-
tion of adenylyl cyclase and positive inotropic effects) is
reduced.
At present, the mechanism underlying this beta-
Figure 6. Changes in adenylyl cyclase activity in sham-operated (SOP)
(n 5 9) and uremic (SNX) rats (n 5 7) after stimulation with isoprenaline
given as means 6 SEM. For details of the protocol, see text. Significant
differences between both groups are indicated by an asterisk (pD2 values:
SOP, 8.18 6 0.25; SNX, 7.95 6 0.24, NS).
Table 3. Activity of Adenylyl Cyclase
SOP
(pmol cAMP/
mg protein/min)
SNX
(pmol cAMP/
mg protein/min)
Basal activity 14.7 6 1.8 18.2 6 3
Forskolin (10 mmol/liter) 282.9 6 26.1 284.4 6 43.6
NaF (10 mmol/liter) 64.3 6 8.3 68.6 6 22.5
GTP (10 mmol/liter) 6.9 6 1.8 5.9 6 2.6
Mn21 (10 mmol/liter) 9.8 6 1.6 8.8 6 1.7
Effect of forskolin, NaF, GTP and Mn21 on adenylyl cyclase activity in membrane
preparations of either SNX (n 5 7) or SOP (n 5 9) rats. Values are given as net
increase in activity after stimulation. The differences between both groups were not
significant. SNX 5 uremic; SOP 5 sham-operated controls.
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adrenoceptor hyporesponsiveness (in the face of unchanged
number and unchanged activity of G proteins and adenylyl
cyclase) is not clear. It could be due to uncoupling of the
receptor from the effector system. Taking into account the
high amount of spare beta-adrenoceptors in the rat heart
(30), “uncoupling” of the beta-adrenoceptors should result
in a rightward shift of the isoprenaline concentration re-
sponse curve but not in a decrease in maximum response
with unchanged pD2 and pEC50 values. Alternatively,
uremic toxins might inhibit beta-adrenoceptor binding
(17,18). This could result in a decrease in maximum
response without change in pD2 and pEC50 values as
observed in our study. In sum, beta-adrenoceptor respon-
siveness (predominantly beta1-adrenoceptors, see preceding
text) in the chronic uremic rat heart is decreased; this
decrease is due to the uncoupling of the beta-adrenoceptor
or to an inhibition of beta-adrenoceptors by uremic toxins.
Conclusions. In summary, in patients on HD as well as in
chronic uremic rats, cardiac beta-adrenoceptor responsive-
ness is decreased; cardiac muscarinic receptor function,
however, is unaltered. The mechanism underlying this
reduced beta-adrenoceptor responsiveness remains unclear;
it might be due to an “uncoupling” of the receptor or to an
inhibition of the receptor by uremic toxins. In chronic
hemodialysis patients, this blunted beta-adrenoceptor re-
sponsiveness may functionally contribute to the impaired
baroreflex response.
APPENDIX
Medication of the patients Patient number and medica-
tion (long-term):
1. Digitoxin 0.07 mg/day, ranitidine 300 mg/day,
calcium-carbonate 3 g/day, alfacalcidol 1 mg/week, reso-
nium A 15 g/day, etilefrin 30 mg/day, meloxicam
7.5 mg/day, Fe31 40 mg/month, vitamin B12 9 mg/week,
folic acid 60 mg/week, L-carnitine 3 g/week.
2. Resonium A 15 g/day, magnesium 120 mg/day,
losartan 100 mg/day, clonidin 0.475 mg/day, calcium-
diactetate 2.85 g/day, medazepam 10 mg/day, amlodipine
10 mg/day, isosorbitdinitrate 80 mg/day, urapidil
180 mg/day, Fe31 40 mg/week, alfacalcidol 1 mg/week,
epoetin beta 21,000 IU/week.
3. Ranitidin 300 mg/day, furosemide 120 mg/day, reso-
nium A 30 g/day, folic acid 320 mg/day, biotin 60 mg/day,
ascorbic acid 200 mg/day, vitamin B1 16 mg/day, vitamin
B2 16 mg/day, vitamin B6 20 mg/day, nicotinamide
100 mg/day, pantothenic acid 20 mg/day, NaHCO3 1.5
g/day, Ca21 1.5 g/day, Fe31 40 mg/week, epoetin alpha
3,000 IU/week, L-carnitine 3 g/week.
4. Furosemide 80 mg/day, allopurinol 200 mg/day,
calcium-diacetate 2.85 g/day, aluminiumhydroxide 1.2
g/day, indometacine 25 mg/day, etilefrine 10 mg/day, Fe31
40 mg/week, alfacalcidol 1 mg/week, epoetin beta 15,000
IU/week.
5. Furosemide (retarded) 250 mg/day, alfacalcidol 2
mg/week, omeprazol 20 mg/day, simvastatin 5 mg/day,
calcium-diacetate 4.3 g/day, resonium A 15 g/day,
aluminium-hydroxide 1.2 g/day, dalteparine-sodium
15 mg/day, Fe31 40 mg/month, epoetin alpha 6,000 IU/
week, thiamine 1.5 mg/day, pyridoxine 10 mg/day, ribofla-
vine 1.7 mg/day, vitamin B12 6 mg/day, ascorbic acid
60 mg/day, nicotinamide 20 mg/day, biotine 0.3 mg/day,
pantothenic acid 10 mg/day, folic acid 0.8 mg/day.
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